Journal of Clinical Case Reports

Case Report   Open Access

Ketamine as Adjunctive Anesthesia in Refractory Complex Regional Pain Syndrome Patients: A Case Series

Schwartzman RJ*, Samudralwar R, Getson P and Alexander GM

Department of Neurology, 245 N. 15th Street, Suite 7102, MS 423 Philadelphia, PA 19102-1192, USA

Abstract

Complex regional pain syndrome most often follows peripheral soft tissue and nerve injury, fractures, and surgical procedures. The pain is out of proportion to the severity of the injury, spreads beyond a nerve or root territory and increases over time. In general, recommendations for anesthesia for these patients requiring surgery include sympathetic blockade or intravenous regional anesthesia as well as sympathetic blockade in conjunction with lidocaine. Quite often surgery for these patients seriously aggravates their condition.

This is a retrospective evaluation of a case series of the use of ketamine as adjunctive anesthesia in twenty five refractory long standing complex regional pain syndrome patients. All patients met the International Association for the Study of Pain criteria for diagnosis. Ketamine was administered intravenously over four hours from the start of the procedure with midazolam and clonidine in addition to their standard anesthesia. At the end of the procedure, an additional dose of midazolam was administered. Lorazepam was used for restlessness if necessary for three nights after the procedure. All twenty five patients had no exacerbation of their symptoms and signs and no spread of their CRPS. This study supports the effective use of ketamine, midazolam and clonidine as adjunctive anesthesia in severe refractory CRPS patients undergoing a surgical procedure.

Abbreviations: CRPS: Complex Regional Pain Syndrome; IASP: International Association for the Study of Pain; IV: Intravenous; EKG: Electrocardiogram; PTSD: Post Traumatic Stress Disorder; NRS: Numeric Rating Scale; ASA Class I-III: American Society Of Anesthesiologists Physical Status Classification; DH: Dorsal Horn; PTNs: Pain Transmission Neurons

Introduction

Complex regional pain syndrome (CRPS) most often follows peripheral soft tissue and nerve injury, fractures, and surgical procedures [1-3]. The pain is out of proportion to the severity of the injury, spreads beyond a nerve or root territory and increases over time [4]. It is characterized as Type I if no specific nerve is injured or Type II if injury to a nerve is demonstrated. There is evidence that Type I patients may have an injury induced small fiber neuropathy [5,6].

Factor analysis reveals that the signs and symptoms cluster into four distinct subgroups: 1) abnormalities in pain processing (allodynia, hyperalgesia and hyperpathia); 2) temperature and skin color changes; 3) edema and sudomotor dysregulation; 4) motor dysfunction and trophic changes [7-9].

In general, recommendations for anesthesia in CRPS patients requiring surgery include sympathetic blockade or intravenous regional anesthesia as well as sympathetic blockade in conjunction with lidocaine [2,10,11]. In an evaluation of 100 patients with upper extremity CRPS that underwent surgery in the affected arm, the recurrence rate was lowered from 72% to 10% in patients receiving postoperative stellate ganglion blocks [11]. Veldman et al. performed surgical procedures after waiting for clinical remission and administration of perioperative intravenous (IV) mannitol. Their recurrence rate was 13% [2]. Although these preemptive anesthetic techniques have often been successful in blocking exacerbation and spread of CRPS following surgical procedures in patients with localized disease, they have often been ineffective in patients with severe refractory CRPS [12]. The purpose of this study was to evaluate ketamine as an adjunctive anesthetic in surgery for severe refractory CRPS patients.

Methods

Following IRB approval from Drexel University College of Medicine, chart reviews were conducted on patients with severe refractory CRPS who underwent surgery and had ketamine as adjunctive anesthesia.

The information obtained included age, gender, inciting injury, CRPS manifestation, duration of disease, spread following surgery, pain intensity pre-operatively and post-operatively and the type of surgery performed. All patients were examined by the same two physicians (RJS and PG) at post surgical visits of 1, 3 and 6 months. They were maintained on their usual pain medication prior to and after surgery.

Inclusion criteria

All patients successfully completed a cardiac evaluation that included a 12-lead electrocardiogram (EKG) and head-up tilt-table testing. They also underwent a psychological clearance. This clearance included a psychological profile and general parameters of intellectual function as well as the Adult Suicide Ideation Questionnaire and the Beck Depression Inventory II. Specific attempts were made to uncover manic depression, schizophrenia, prior drug abuse and severe post traumatic stress disorder (PTSD). Depressed patients were included but the aforementioned psychiatric diagnoses were exclusion criteria. The results of neuropsychological testing in these and other CRPS patients are summarized by Libon et al. [13].

All patients met the International Association for the Study of Pain (IASP) criteria for the diagnosis of CRPS [14] as determined by the same two physicians (RJS & PG). The age range was 17 to 80 years. All patients had to have long standing (greater than 7 years) of active CRPS in at least one extremity that was refractory to treatment. A refractory designation included failure of: 1) non-medical (physical therapy and psychological approaches); 2) pharmacological mono or combined therapy with nonsteroidal anti-inflammatory drugs, various antidepressants, anticonvulsants (gabapentin, carbamazepine), low or high potency opioids; 3) and one of three interventional procedures that included selective nerve blocks, epidural anesthesia, brachial plexus blocks, sympathetic ganglion blocks, intravenous regional sympathetic or sodium channel blocks, spinal cord stimulation, surgical sympathectomy or intrathecal drug delivery systems.

The average daily pain intensity had to be 5 points or greater on a Likert numeric rating scale (NSR) (endpoints: 0–no pain and 10–worst pain imaginable). All patients were in the florid CRPS category by cluster analysis [15]. All patients met ASA class I-III (American Society of Anesthesiologists physical status classification).

Exclusion criteria

Patients were excluded if they suffered significant cardiovascular, pulmonary, renal disease or psychiatric disorders. Depression was not an exclusion factor while manic-depression, schizophrenia, prior drug abuse and severe PTSD were. Further exclusion criteria included contraindications to ketamine use (severe arterial hypertension, hyperthyroidism, ischemic heart disease, heart failure and glaucoma) as well as allergies to ketamine or midazolam. Patients were excluded if: they were unable to complete the pain questionnaire, were unavailable for follow up, or if the record of surgery, medication and status was incomplete.

Infusion protocol (25 patients) as adjunctive anesthesia

Clonidine (0.1 mg) and midazolam (2 mg) were administered intravenously during the induction of anesthesia. Ketamine was infused at the rate of 50 mg/hour. An additional dose of midazolam (2 mg) was given IV at the end of the procedure. Clonidine potentiates NMDA receptor blockade, has pain relieving effects and prevents the neurotoxic side effects noted in rodents [16]. Midazolam (2 mg) is utilized prior to the ketamine infusion for sedation and to block agitation and vivid dreams.

Following the procedure, patients underwent two booster infusions at two weeks, one month and three months (total of six infusions). These consisted of IV ketamine (50 mg/hour to a total of 200 mg) over 4 hours. IV midazolam (2 mg) was given at the start and at the termination of the 4 hours for boosters. The infusion suite for boosters is attended by two nurses who are Advanced Cardiac Life Support certified. The patients' cardiac rhythm (EKG), oxygen saturation, and blood pressure are continuously monitored. Complete blood count, electrolyte profiles and liver enzymes are obtained at the end of the infusion. Ondansetron (4 mg) is administered IV for nausea if necessary. Patients are accompanied to the suite and escorted home by a relative or friend.

Results

Preoperative pain scores revealed intensities ranging from 5 to 9 on the Likert NRS. Twenty four of 25 patients had pain scores above 5/10 and had difficulty with activities of daily living. Seventeen of 25 patients had generalized disease in that CRPS affected all four extremities and

the face. All patients returned to their preoperative pain level following surgery. There was no exacerbation or spread of their CRPS at their last evaluation (3 months) in either affected or non-affected areas. This was determined by evaluation of mechanical and thermal allodynia; hyperalgesia to pinprick and evaluation of the wind-up phenomena (2 algesic mechanical stimuli per second to a total of 6 pinpricks) in non-affected or formally affected extremities. Autonomic dysregulation consisting of temperature and color change as well as hyperhidrosis was evaluated clinically in formerly unaffected extremities, face and the torso. Initiation, facility and strength of movement were assessed in all extremities clinically. Neurogenic edema was evaluated clinically in formerly affected and unaffected areas. (Table 1)

One patient with demyelinating disease underwent hip replacement. She was unable to walk prior to surgery but at six months was able to return to work full time as a kindergarten teacher and walk independently for 2 blocks with a walker. Four patients had radiculopathies as the cause of their CRPS which also improved to a clinically significant degree (30%) for approximately 3 months following surgery. The CRPS pain returned to preoperative levels in all patients at 6 months.

Side effects of treatment

Side effects of this protocol (and booster therapy) are headache, nausea, tiredness, difficulty sleeping and dysphoria which occur in approximately 25% of patients and are either self limited or controlled with 2-4 mg of lorazepam once or twice a day for one or two days [17]. At one week the patients had none of the usual adverse effects that may be seen during booster infusion. These include nausea, tiredness, sleep architecture disruption or dysphoria [4]. We ascribe this to careful psychiatric screening, the administration of midazolam and clonidine during the procedure, a quiet controlled atmosphere in the infusion suite and 2-4 mg of midazolam after the procedure. Lorazepam (2 mg) may be used prior to sleep for two or three days after the procedure.

The review evaluated 25 females and 2 males. The usual female to male ratio in CRPS is 4:1 [18]. The average age of the patients was 46.2 ranging from 21 to 67 years. They suffered with CRPS for at least 7 years and had failed standard therapy as defined above. All patients underwent an operative procedure unrelated to the treatment of CRPS. All patients were evaluated for pre and post operative pain scores and for spread of their CRPS to initially unaffected body parts.

Discussion

The major findings of this study are that ketamine used as adjunctive anesthesia in refractory CRPS patients undergoing surgery was successful in reducing pain and blocking spread in severely affected long-standing patients. Ketamine, the currently most potent clinically available NMDA-antagonist, has a well established role in the treatment of acute and chronic pain including the pain seen in CRPS [19-22]. It has been shown to reduce wind-up and punctate hyperalgesia for 7 days following surgery (Table 2) [23]. Its usage in higher intraoperative dosage for major abdominal surgery reduced the area of wound hyperalgesia and prevented the initiation and maintenance of chronic pain [24]. It has also been effectively used in patients undergoing spinal fusion and other orthopedic procedures [25, 26]. Recently it has been utilized during elective coronary artery bypass graft surgery and has been demonstrated to attenuate the usual proinflammatory cytokine response during and after this procedure [27].

The primary cause of persistent post surgical pain is neuropathic

Patient #	Age/ Gender	CRPS Duration (Years)	Inciting Injury	Status of Spread Baseline
1	21 F	10	Trauma: Right Wrist Ruptured Tendon	RUE
2	67 F	11	Brachial Plexus Traction Injury, Cervical Plexus Injury: Trapezius Ridge, Lower Back, Bilateral UE	Lateral LLE, Shoulders, Neck, and Back
3	28 F	12	Surgery and Lymph Node Removal of Left Breast	Bilateral UE, Chest, Neck, and Back
4	62 F	24	MVA: Back and All Limbs	Face
5	62 F	23	Brachial plexus Traction Injury: Bilateral Upper Extremities	Bilateral Lower Extremities and Face
6	53 F	9	Disc Herniation: RUE	RLE
7	29 F	14	Cholecystectomy: Midepigastric Region	All Limbs, lower back, right Lower Face
8	30 F	11	MVA: Brachial Plexus Traction Injury/RUE	RLE and Lower Back
9	63 F	10	Trauma: Lifting/ Neck and Upper Back	Bilateral UE
10	41 F	15	Trauma: Torn Ligament/RUE	LUE, Bilateral LE
11	45 F	9	Trauma: Brachial Plexus Traction Injury/Neck and RUE	RUE and Bilateral LE
12	54 F	22	Trauma + Cellulitis /LUE, LLE	RUE,RLE, Back
13	26 F	14	Trauma: Right Thumb and Right Ankle	All Limbs and Back
14	60 M	13	Thoracic Outlet Surgery: Upper Body	4 Limbs, Central, Hearing Loss
15	38 F	15	Brachial Plexus Injury: RUE ; MVA: LUE +Bilateral LLE/Central Annular Tear at C5-6 + C6-7	All Limbs and Face
16	47 F	13	MVA	All Limbs and Face
17	34 F	9	MVA: LUE	All Limbs and Face
18	50 M	7	MVA: Herniated Cervical C6-7 with Discogenic Disease at C5-6 + C7-T1	All Limbs
19	24 F	7	Foot Surgery: Full Body, Dystonic, R>L	All Limbs and Face
20	54 F	8	MVA: Cervical, Thoracic, Lumbar, L Knee Problems Cervical Plexus Injury: RUE, LLE Sympathetic	
21	52 F	15	MVA	All Limbs and Face
22	58 F	8	Unknown	All Limbs and Face
23	41 F	8	MVA-Brachial Plexus Injury/LUE	All Limbs and Face
24	59 F	8	Brachial Plexus Traction Injury	All Limbs
25	44 F	8	MVA: RUE	RUE, RLE

Table 1: Demographics.

Patient #	Amt Ketamine Utilized	Surgery Performed w/Ketamine
1	200mg	Denervation of trapezium, lower right wrist implantation of palmer cutaneous branch of the median nerve into the pronator quadratus muscle
2	200mg	Left Knee Replacement
3	200mg	Laparoscopic sigmoid resection with coloproctostomy and suture rectopexy of rectum to the sacral promontory
4	200mg	Knee Replacement
5	200mg	Left Total Knee Replacement
6	200mg	Total Hip Replacement
7	200mg	Placement of Dental Implants
8	200mg	Tracheal Reconstruction
9	200mg	Lumbar spine surgery
10	200mg	Cervical spinal cord stimulator insertions
11	200mg	Sinus surgery
12	200mg	Colonoscopy and bladder stones
13	200mg	Wisdom teeth removal
14	100mg	Arthroscopic Repair of Left Rotator Cuff
15	100mg	Cervical Discectomy
16	90mg	Full Mouth Dental Extraction
17	100mg	Cervical Discectomy + Multilevel Fusion
18	100mg	Cervical Discectomy
19	150mg	Surgical Resection of Sup. Peroneal Nerve
20	80mg	Arthroscopic Resection of Plica from Left Knee
21	60mg	Full Mouth Dental Extraction
22	80mg	Needle Biopsy of Breast
23	100 - 125mg	Breast Reduction
24	80mg	Laparoscopic Cholecystectomy, Hernia Repair
25	100mg	Gastroparesis/ Laparoscopic Fundal Plycation, Arthroscopic Meniscectomy

Table 2: Surgical Procedures with Adjunctive Ketamine.

from damage to the nerves in the operative field or C-δ and A-δ nociceptors in soft tissue [28-30]. Recent studies in rodent models of post surgical pain have elucidated its different components emanating from the skin incision and that from deep fascia muscle and tendon [31,32]. Endothelin-1 (ET-1) is endogenous peptides whose effects are mediated by the

G-protein-coupled receptors ET_A and ET_B [33] and is found in the epidermis, dermis and subcutaneous vasculature [34]. It appears to be pivotal in the mechanism that induces post-incision primary allodynia and contributes to central sensitization and secondary hyperesthesia [31,35]. There is also evidence that post-incision primary mechanical hyperalgesia is due to hydrogen ion sensitive channels rather than activation of ET_A receptors [36-38].

In a series of behavioral and electrophysiological experiments following incision of the glabrum skin of rodents, Brennan and colleagues demonstrated: 1) spontaneous activity of C-δ and A-δ nociceptor afferents; 2) behavioral guarding and spontaneous activity in nociceptive afferents and pain transmission neurons of the Dorsal Horn (DH) following deep tissue trauma while 3) decreased heat and mechanical withdrawal latency were associated only with skin incision [32,39-44]. Clinical studies support this experimental work in that deep tissue injury is correlated with both post surgical pain and opiods consumption [45-48].

All of the patients in this study had severe long standing disease of at least 7 years duration and a Likert NRS ≥ 5/10. It would be expected from both clinical and experimental evidence that they had ectopic activity in injured axons [49], activation of spinal microglia and astrocytes [50-54] that in concert with changes in MAP kinases are a major component of central sensitization and the induction and maintenance of neuropathic pain [29,53,55]. They also would be expected to have modifications in pain circuitry as a consequence of altered gene expression and the death of inhibitory DH interneurons [54,56,57].

A great majority of these patients were on significant doses of opiods at the time of surgery and maintained their usage afterwards. Recent experimental work has demonstrated that chronic morphine consumption enhances both p38 and extracellular receptor kinase phosphorylation in pain transmission neurons (PTNs) of the DH (the latter a marker of central sensitization) and in microglia. This data was correlated with decreased resolution of postoperative allodynia [58]. Chronic morphine consumption also enhances MAPK signaling that increases the expression of membrane receptors for ATP, cytokines and chemokines-all important for the maintenance of chronic pain [53]. Recently phosphokinase C epsilon, expressed in PTNs, has also been suggested as a mechanism that enhances the nociceptive response to a second injury [59]. All of these patients suffered an original injury, a second surgical injury and most were morphine dependant and tolerant at the time of the surgery. Experimentally and clinically blockade of the NMDA receptor has been shown to reduce pain under these circumstances [60,61]. This study demonstrated the effectiveness of ketamine, midazolam and clonidine in small doses as an adjunct in anesthesia in blocking pain exacerbation and spread of CRPS from a variety of surgical procedures.

The limitations of the study are those inherent in a retrospective non-randomized uncontrolled case series. The CRPS patient population studied is not representative of that seen in most pain centers (more severe and of longer duration). No quantification of static and dynamic mechano allodynia, thermal allodynia or deep muscle sensitization at the site of surgery and at a distance was obtained. The role of clonidine and midazolam in preventing the spread of pain following surgical procedures could not be ascertained. A complete double blind randomized controlled trial would be necessary to determine ketamine's effectiveness as an adjunctive anesthetic in refractory CRPS patients. The trial would be difficult to design due to ethical concerns as ketamine adjunctive anesthesia appears to be more effective than past procedures in severely affected patients.

Acknowledgement

References

1. Schwartzman RJ, McLellan TL (1987) Reflex sympathetic dystrophy. A review. Arch Neurol 44: 555-561.

2. Veldman PH, Goris RJ (1995) Surgery on extremities with reflex sympathetic dystrophy. Unfallchirurg 98: 45-48.

3. Birklein F, Schmelz M, Schifter S, Weber M (2001) The important role of neuropeptides in complex regional pain syndrome. Neurology 57: 2179-2184.

4. Schwartzman RJ, Erwin KL, Alexander GM (2009) The natural history of complex regional pain syndrome. Clin J Pain 25: 273-280.

5. Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, et al. (2006) Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain 120: 235-243.

6. Oaklander AL, Fields HL (2009) Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol 65: 629-638.

7. Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, et al. (1999) Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive? Pain 83: 211-219.

8. Bruehl S, Harden, RN, Galer BS, Saltz S, Bertram M, et al. (1999) External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain 81: 147-154.

9. Harden RN, Bruehl S (2005) Diagnostic criteria: the statistical derivation of the four criterion factors in CRPS: Current Diagnosis and Therapy. IASP Press, Seattle.

10. Katz MM, Hungerford DS (1987) Reflex sympathetic dystrophy affecting the knee. J Bone Joint Surg Br 69: 797-803.

11. Reuben SS, Rosenthal EA, Steinberg RB (2000) Surgery on the affected upper extremity of patients with a history of complex regional pain syndrome: a retrospective study of 100 patients. J Hand Surg Am 25: 1147-1151.

12. Cramer G, Young BM, Schwarzentraub P, Oliva CM, Racz G (2000) Preemptive analgesia in elective surgery in patients with complex regional pain syndrome: a case report. J Foot Ankle Surg 39: 387-391.

13. Libon DJ, Schwartzman RJ, Eppig J, Wambach D, Brahin E, et al. (2010) Neuropsychological deficits associated with Complex Regional Pain Syndrome. J Int Neuropsychol Soc 16: 566-573.

14. Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, et al. (2010) Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain 150: 268-274.

15. Burton AW, Bruehl S, Harden RN (2005) Current diagnosis and therapy of complex regional pain syndrome: refining diagnostic criteria and therapeutic options. Expert Rev Neurother 5: 643-651.

16. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW (2001) A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 895: 264-267.

17. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, et al. (2009) Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 147: 107-115.

18. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, et al. (2007) The incidence of complex regional pain syndrome: a population-based study. Pain 129: 12-20.

19. Hocking G, Cousins MJ (2003) Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97: 1730-1739.

20. Himmelseher S, Durieux ME (2005) Ketamine for perioperative pain management. Anesthesiology 102: 211-220.

21. Schwartzman RJ, Patel M, Grothusen JR, Alexander GM (2009) Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. Pain Med 10: 401-412.

22. Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, et al. (2010) An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 14: 302-307.

23. Stubhaug A, Breivik H, Eide PK., Kreunen M, Foss A (1997) Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 41: 1124-1132.

24. Lavand'homme P, De Kock M, Waterloos H (2005) Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery. Anesthesiology 103: 813-820.

25. Urban MK, Ya Deau JT, Wukovits B, Lipnitsky JY (2008) Ketamine as an adjunct to postoperative pain management in opioid tolerant patients after spinal fusions: a prospective randomized trial. HSS J 4: 62-65.

26. Perrin SB, Purcell AN (2009) Intraoperative ketamine may influence persistent pain following knee arthroplasty under combined general and spinal anaesthesia: a pilot study. Anaesth Intensive Care 37: 248-253.

27. Welters ID, Feurer MK., Preiss V, Muller M, Scholz S, et al. (2011) Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth 106: 172-179.

28. Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367: 1618-1625.

29. Woolf CJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain 152: S2-15.

30. Oaklander AL, Fields HL (2010) Reply: Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol 68: 116-117.

31. Mujenda FH, Duarte AM, Reilly EK, Strichartz GR (2007) Cutaneous endothelin-A receptors elevate post-incisional pain. Pain 133: 161-173.

32. Brennan TJ (2011) Pathophysiology of postoperative pain. Pain 152: S33-40.

33. Lüscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440.

34. Ahn SS, Machleder HI, Concepcion B, Moore WS (1994) Thoracoscopic cervicodorsal sympathectomy: preliminary results. J Vasc Surg 20: 511-517.

35. Zhou Z, Davar G, Strichartz G (2002) Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. J Neurosci 22: 6325-6330.

36. Steen KH, Steen AE, Reeh PW (1995) A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. J Neurosci 15: 3982-3989.

37. Woo YC, Park SS, Subieta AR, Brennan TJ (2004) Changes in tissue pH and temperature after incision indicate acidosis may contribute to postoperative pain. Anesthesiology 101: 468-475.

38. Julius D, McCleskey E (2006) Cellular and molecular properties of primary afferent neurons in Wall and Melzack's textbook of pain. Elsevier/Churchill Livingstone, Philadelphia.

39. Pogatzki EM, Gebhart GF, Brennan TJ (2002) Characterization of Adelta- and C-fibers innervating the plantar rat hindpaw one day after an incision. J Neurophysiol 87: 721-731.

40. Pogatzki EM, Vandermeulen EP, Brennan TJ (2002) Effect of plantar local anesthetic injection on dorsal horn neuron activity and pain behaviors caused by incision. Pain 97: 151-161.

41. Vandermeulen EP, Brennan TJ (2000) Alterations in ascending dorsal horn neurons by a surgical incision in the rat foot. Anesthesiology 93: 1294-1302.

42. Xu J, Brennan TJ (2009) Comparison of skin incision vs. skin plus deep tissue incision on ongoing pain and spontaneous activity in dorsal horn neurons. Pain 144: 329-339.

43. Xu J, Richebe P, Brennan TJ (2009) Separate groups of dorsal horn neurons transmit spontaneous activity and mechanosensitivity one day after plantar incision. Eur J Pain 13: 820-828.

44. Xu J, Brennan TJ (2010) Guarding pain and spontaneous activity of nociceptors after skin versus skin plus deep tissue incision. Anesthesiology 112: 153-164.

45. Kawamata M, Takahashi T, Kozuka Y, Nawa Y, Nishikawa K, et al. (2002) Experimental incision-induced pain in human skin: effects of systemic lidocaine on flare formation and hyperalgesia. Pain 100: 77-89.

46. Kawamata M, Watanabe H, Nishikawa K., Takahashi T, Kozuka Y, et al. (2002) Different mechanisms of development and maintenance of experimental incision-induced hyperalgesia in human skin. Anesthesiology 97: 550-559.

47. Dorr LD, Maheshwari AV, Long WT, Wan Z, Sirianni LE (2007) Early pain relief and function after posterior minimally invasive and conventional total hip arthroplasty. A prospective, randomized, blinded study. J Bone Joint Surg Am 89: 1153-1160.

48. Ogonda L, Wilson R, Archbold P, Lawlor M, Humphreys P, et al. (2005) A minimal-incision technique in total hip arthroplasty does not improve early postoperative outcomes. A prospective, randomized, controlled trial. J Bone Joint Surg Am 87: 701-710.

49. Sorkin LS, Xiao WH, Wagner R, Myers RR (1997) Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81: 255-262.

50. Watkins LR, Maier SF (2003) Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2: 973-985.

51. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, et al. (2003) P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424: 778-783.

52. Jin SX, Zhuang ZY, Woolf CJ, Ji RR (2003) p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23: 4017-4022.

53. Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR (2009) MAP kinase and pain. Brain Res Rev 60: 135-148.

54. Del Valle L, Schwartzman RJ, Alexander G (2009) Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav Immun 23: 85-91.

55. Gao YJ, Ji RR (2010) Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126: 56-68.

56. Costigan M, Befort K, Karchewski L, Griffin RS, D'Urso D, et al. (2002) Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci 3: 16.

57. Scholz J, Broom DC, Youn DH, Mills CD, Kohno T, et al. (2005) Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 25: 7317-7323.

58. Horvath RJ, Landry RP, Romero-Sandoval EA, DeLeo JA (2010) Morphine tolerance attenuates the resolution of postoperative pain and enhances spinal microglial p38 and extracellular receptor kinase phosphorylation. Neuroscience 169: 843-854.

59. Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139: 267-284.

60. Schwartzman RJ, Alexander GM, Grothusen J (2006) Pathophysiology of complex regional pain syndrome. Expert Rev Neurother 6: 669-681.

61. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, et al. (2009) Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 145: 304-311.